SSG
CORV

Summit Securities Group’s Correvio Pharma Corp. Ordinary Shares (Canada) CORV Stock Holding History

Summit Securities Group’s Portfolio CORV Stock Details CORV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-600
Closed -$4K – 630
2013
Q4 		$4K Buy
+600
New +$3.15K ﹤0.01% 411

Other funds holding CORV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
FIG
Fortress Investment Group New York $531M AUM 12.95% 1-Year Est. Return
ACM
Alistair Capital Management Dallas, Texas $391M AUM 5.89% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return

Summit Securities Group's CORV Position: Q1 2014 in Review

Summit Securities Group sold out of Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) in Q1 2014, closing a stake of 600 shares — an estimated $4K sold.

Summit Securities Group first reported a position in CORV in Q4 2013 and held it in 1 quarter. The position peaked at $4K in Q4 2013. 30 funds tracked by Wall St. Rank hold CORV as of Q1 2014.

  • Summit Securities Group reported no remaining Correvio Pharma Corp. Ordinary Shares (Canada) position as of Q1 2014 after selling out during the quarter.
  • Summit Securities Group sold 600 Correvio Pharma Corp. Ordinary Shares (Canada) shares in Q1 2014, an estimated $4K.
  • Summit Securities Group first reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) in Q4 2013 and held it in 1 quarter.
  • Summit Securities Group's Correvio Pharma Corp. Ordinary Shares (Canada) position peaked at $4K in Q4 2013.
  • 30 funds tracked by Wall St. Rank held Correvio Pharma Corp. Ordinary Shares (Canada) as of Q1 2014.

Based on Summit Securities Group's 13F filing for Q1 2014, filed 17 Apr 2014.